Group 1 - The core viewpoint of the news is that Dongyangguang Changjiang Pharmaceutical Co., Ltd. is set to complete its last trading day on the Hong Kong Stock Exchange and will officially list as "Dongyangguang Pharmaceutical" on August 7, marking a significant innovation in the capital market with its "H-share absorption merger and introduction listing" model [1] - The company aims to achieve overall listing by merging its Hong Kong-listed subsidiary, Dongyangguang Changjiang Pharmaceutical, into its parent company, Dongyangguang Pharmaceutical, and issuing H-shares to minority shareholders of the subsidiary [1] - This move is seen as a way to break traditional capital operation barriers, reduce financial friction costs associated with acquisitions, and ensure shareholder rights, providing a reference model for industrial integration and international development [1] Group 2 - After listing in Hong Kong, Dongyangguang Pharmaceutical is expected to gain long-term capital support and achieve integrated-driven industrial upgrades, combining its R&D capabilities with the nationwide sales network of Dongyangguang Changjiang Pharmaceutical [2] - The company focuses on drug research, production, and commercialization, specializing in innovative drugs, including improved new drugs, generic drugs, and biosimilars, with a strategic focus on infection, chronic diseases, and oncology [2] - Dongyangguang Pharmaceutical aims to establish a global operational platform and is committed to becoming a first-class international innovative pharmaceutical company [2]

Group 1 - Dongyangguang Pharmaceutical has completed its last trading day and officially launched the first case of "H-share absorption merger privatization + introduction listing" in the Hong Kong market [1] - The company plans to list on the Hong Kong Stock Exchange on August 7 under the name "Dongyangguang Pharmaceutical" (06887), creating a new paradigm for asset securitization in Chinese innovative pharmaceutical companies [1] - The absorption merger allows Dongyangguang Pharmaceutical to issue H-shares to minority shareholders of its subsidiary Dongyangguang Changjiang Pharmaceutical, facilitating overall listing [1] Group 2 - Industry insiders note that this move breaks traditional capital operation time barriers, reduces friction costs in acquisitions, and effectively safeguards shareholder rights [1] - The listing is seen as a response to the national strategy of optimizing capital market structure and provides a reference model for industrial integration and international development [1] - After the listing, Dongyangguang Pharmaceutical is expected to gain long-term capital support and achieve integrated industry upgrades, creating a closed loop of "research and development - production - sales" [1][2] Group 3 - Dongyangguang Pharmaceutical is engaged in drug research, production, and commercialization, focusing on innovative drugs, including modified new drugs, generic drugs, and biosimilars [2] - The company adheres to principles of innovation, internationalization, and sustainability, with a strategic focus on treating infections, chronic diseases, and tumors [2] - Dongyangguang Pharmaceutical aims to become a world-class innovative pharmaceutical company with a mature and well-circulated business model [2]

Core Viewpoint - Dongyangguang Pharmaceutical is pioneering an innovative capital operation by launching the first "H-share absorption merger privatization + introduction listing" in the Hong Kong market, aiming for overall listing and resource integration [1][2] Group 1: Capital Market Operations - Dongyangguang Pharmaceutical completed the last trading day of Dongyangguang Changjiang Pharmaceutical on July 29, officially starting its innovative capital operation [1] - The company plans to list as "Dongyangguang Pharmaceutical" (stock code: 06887.HK) on the Hong Kong Stock Exchange on August 7, creating a new paradigm for asset securitization in Chinese innovative pharmaceutical companies [1] - The absorption merger allows the listing entity to issue H-shares to minority shareholders of Dongyangguang Changjiang Pharmaceutical, facilitating a seamless transition to overall listing [1] Group 2: Strategic Implications - This move breaks traditional capital operation time barriers, reduces funding friction costs associated with acquisitions, and effectively safeguards shareholder rights [1] - The operation serves as a model for industrial integration and international development, aligning with national strategies to optimize capital market structures [1] Group 3: Company Profile - Dongyangguang Pharmaceutical focuses on drug research, production, and commercialization, specializing in innovative drugs, including improved new drugs, generic drugs, and biosimilars [2] - The company adheres to principles of innovation, internationalization, and sustainability, driven by independent research and development, and targets treatment areas such as infections, chronic diseases, and tumors [2] - Dongyangguang Pharmaceutical has established a mature and well-circulated business model, progressing towards the goal of becoming a world-class innovative pharmaceutical company [2]

人民财讯7月30日电，企查查APP显示，近日，乳源瑶族自治县东阳光（600673）新宙邦（300037）电 子材料有限公司成立，注册资本8000万元，经营范围包含：电子专用材料制造；电子专用材料销售；电 子专用材料研发等。企查查股权穿透显示，该公司由新宙邦等共同持股。 ...

人民财讯7月30日电，深交所公告，因恒生综合小型股指数实施成份股调整，港股通标的证券名单发生 调整并自2025年7月30日起生效，调出东阳光（600673）长江药业。 ...

每经AI快讯，7月30日，深交所公告，港股通标的证券名单发生调整并自2025年07月30日起生效，调出 东阳光（600673）长江药业。 ...

智通财经7月30日电，深交所公告，港股通标的证券名单发生调整并自2025年07月30日起生效，调出东 阳光长江药业。 ...

Group 1 - Dongyangguang Pharmaceutical has completed its last trading day and is set to launch on the Hong Kong Stock Exchange, marking the first instance of "H-share absorption merger privatization + introduction listing" in the market [1] - The company plans to list as "Dongyangguang Pharmaceutical" (stock code: 06887.HK) on August 7, 2023, creating a new paradigm for asset securitization among Chinese innovative pharmaceutical companies [1] - This listing does not involve new share issuance or fundraising; instead, it involves the absorption merger of its Hong Kong-listed subsidiary, Dongyangguang Changjiang Pharmaceutical, allowing small shareholders to exchange their shares for H-shares [1] Group 2 - Industry insiders note that this approach breaks traditional capital operation time barriers, reduces funding friction costs associated with acquisitions, and effectively safeguards shareholder rights [1] - The move is seen as a model for resource integration and capital upgrade, providing a reference for industrial consolidation and international development, aligning with national strategies to optimize capital market structures [1] - After the Hong Kong listing, Dongyangguang Pharmaceutical is expected to gain long-term capital support and achieve integrated industry upgrades, combining its R&D capabilities with the nationwide sales network of Dongyangguang Changjiang Pharmaceutical [1][2]

| 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | --- | --- | --- | --- | --- | --- | | 600682 | 南京新白 | 7.43 | -2.24% | 77.48万 | 5.74亿 | | 000632 | 三木集团 | 4.06 | -2.17% | 17.94万 | 7290.78万 | | 002758 | 浙农股份 | 9.22 | -1.50% | 6.39万 | 5878.08万 | | 600881 | 亚泰集团 | 1.83 | -1.08% | 60.58万 | 1.11亿 | | 000421 | 南京公用 | 6.83 | -1.01% | 9.45万 | 6416.93万 | | 600051 | 宁波联合 | 7.66 | -0.91% | 5.58万 | 4261.73万 | | 000753 | 漳州发展 | 5.64 | -0.88% | 28.67万 | 1.61亿 | | 600620 | 天宸股份 | 6.34 | -0.78% | 12.94万 | 8185.07万 | | 600770 | 综 ...

| 证券代码：600673 | 证券简称：东阳光 | | 编号：临 2025-48 号 | | --- | --- | --- | --- | | 债券代码：242444 | 债券简称：25 东科 | 01 | | 广东东阳光科技控股股份有限公司 关于控股股东及其一致行动人部分股份解质押的公告 截至本公告披露日，公司控股股东累计质押股数数量为 551,798,054 股， 占其持股数量的 89.34%；控股股东及其一致行动人累计质押股数数量为 1,244,388,597 股，占合计持股数量比例为 78.36%。 一、本次股份解质押基本情况 广东东阳光科技控股股份有限公司（以下简称"公司"）于近日收到控股股 东深圳东阳光实业及其一致行动人宜昌药业股份的通知，获悉其将其持有的公司 部分无限售流通股进行了解质押，具体事项如下： | 股东名称 | 深圳市东阳光实业发展有限公司 | 宜昌东阳光药业股份有限公司 | | --- | --- | --- | | 本次解质押股数 | 10,000,000 股 | 10,000,000 股 | | 占其所持股份比例 | 1.62% | 1.83% | | 占公司总股本比例 | ...